Read the latest on our clinical trials | Harbour Cancer & Wellness

Developing the future of cancer treatment

We’re proud to be participating in clinical trials that provide promising new treatments for cancer.

Conducting clinical trials provides our patients with access to cutting-edge medicines and cancer treatments that are otherwise unavailable in New Zealand.

Participants in clinical trials contribute to the collective research effort aimed at developing treatments that will ultimately save lives.

An oncologist discussing our cancer trials

FOR PATIENTS

If you would like to discuss if one of our trials is right for you, please speak with your treating medical team to arrange a referral. We can not take self-referrals.

LEARN ABOUT JOINING A CLINICAL TRIAL

FOR CLINICIANS

If referring a patient for participation in a clinical trial, please send a referral letter, including medical history, histopathology and molecular pathology results, to trials.referral@harbourcancer.co.nz

Harbour Cancer & Wellness

You may have noticed a change in our name recently, to Harbour Cancer & Wellness. Our vision is to provide cutting-edge treatments within a holistic and integrated model of cancer care.

In this update, we want to tell you more about our integrated Wellness services, introduce some new people in our team, and also share

CURRENT CLINICAL TRIALS

SHOW FILTERSHIDE FILTERS

RESULTS

BGB-A317-26808

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumours.

This is an open-label, multicentre, nonrandomized dose escalation and dose expansionstudy to evaluate BGB-26808 as monotherapy or in combination with tislelizumab inparticipants with advanced solid tumours. The main purpose of this study is to explore therecommended dosing for BGB-26808.

Tumour Stream: Gastro-intestinal
Phase: 1
Status: Recruiting
Trial ID: NCT05981703

BGB-43395

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumour Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumours.

This aim of this study is to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works when given on its own or given with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer or other advanced solid tumours. The main purpose is to explore the recommended dosing for BGB-43395.

Tumour Stream: Breast (metastatic HR+/HER2-)
Phase: 1a/1b
Status: Recruiting
Trial ID: NCT06120283

MK-1022

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers.

The goals of this study are to learn about the safety of patritumab deruxtecan (a HER3-directed antibody-drug conjugate), how well people can tolerate treatment, and how many people respond to treatment. To be eligible for this trial people need to have specific types of advanced cancer (cancer that has spread to other parts of the body). These cancers are unresectable or metastatic colorectal cancer, advanced and/or unresectable biliary tract cancer, or hepatocellular carcinoma not amenable to locoregional therapy.

Tumour Stream: Gastro-intestinal
Stage: Phase 1/Phase 2
Status: Recruiting
Trial ID: NCT06596694

V940-007

A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC).

This is a study of V940 (an individualised neoantigen therapy) plus pembrolizumab in patients with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC). There are three treatment groups in the trial: the first gets V940 + pembrolizumab before and after surgery (surgical resection with/without adjuvant radiation therapy), the second gets pembrolizumab before and after surgery, and the third gets standard care. The study will evaluate the effectiveness and safety of the different treatments.

Tumour Stream: Melanoma/skin
Phase: Phase 2/Phase 3
Status: Trial stopped
Trial ID: NCT06295809

Keyvibe-010

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010).

The main purpose of this study is to compare the duration of recurrence-free survival in patients with high-risk resected Stage IIB, IIC, III or IV melanoma during treatment with pembrolizumab plus vibostolimab versus pembrolizumab alone.

Tumour Stream: Melanoma/skin
Phase: Phase 3
Status: Trial stopped
Trial ID: NCT05665595

V940-001

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma.

This study is investigating whether treatment with V940 (an individualised neoantigen therapy) plus pembrolizumab is safe and prevents cancer from returning in people with high-risk melanoma. The study will also assess whether V940 + pembrolizumab is better than pembrolizumab alone at preventing the cancer from returning.

Tumour Stream: Melanoma/skin
Phase: Phase 3
Status: Recruitment closed
Trial ID: NCT05933577

V940-002

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer.

The goal of this study is to evaluate V940 plus pembrolizumab versus pembrolizumab alone for the adjuvant (post surgery) treatment of completely resected Stage II, IIIA, IIIB (with nodal involvement) non-small cell lung cancer (NSCLC). The main outcome being investigated is the rate of investigator-assessed disease-free survival.

Tumour Stream: Lung/Thoracic
Phase: Phase 3
Status: Recruiting
Trial ID: NCT06077760

BG-60366-101

This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC).

This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NSCLC.

Tumour Stream: Lung cancer (EGFR+ NSCLC)
Phase: 1a/1b
Status: Recruiting
Trial ID: NCT06685718

MK-2870-011

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10.

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Tumour Stream: Breast cancer (TNBC)
Phase: 3
Status: Recruiting
Trial ID: NCT06841354

V940-012

A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma.

Researchers want to learn if V940 with pembrolizumab can stop advanced melanoma from growing or spreading. A standard (or usual) treatment for advanced melanoma is immunotherapy, e.g. pembrolizumab. V940 is a study treatment designed to help a person's immune system attack their specific cancer.

The goal of this study is to learn if people who receive V940 with pembrolizumab live longer without the cancer growing or spreading than people who receive placebo with pembrolizumab.

Tumour Stream: Melanoma/skin
Phase: 2
Status: Recruiting
Trial ID: NCT06961006

MORE INFORMATION

The NZ Cancer Society website has more information about clinical trials in New Zealand.

HELPFUL LINKS

STAY IN TOUCH

If you would like to get in contact with us and discuss any of our services further please feel free to contact us on 09 220 3333 or email us at hello@harbourcancer.co.nz / wellness@harbourcancer.co.nz

We look forward to hearing from you.

View Our Locations

Clinical Trials